Annales De Dermatologie Et De Venereologie最新文献

英文中文

Lichenoid drug reaction induced by apalutamide: report of three cases and review of the literature 阿帕鲁胺致地衣类药物反应3例报告并文献复习。

IF 2.8 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2025-11-05 DOI: 10.1016/j.annder.2025.103389

A. Dangien, P. Sohier, C. Metzger, M. Bennamoun, B. Oules, P. Charles, N. Dupin, C. Isnard

引用次数: 0

Concurrent red scrotum and red ear syndromes: successful resolution with amitriptyline 并发红阴囊和红耳综合征：阿米替林成功解决

IF 2.8 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2025-10-10 DOI: 10.1016/j.annder.2025.103373

C. Skayem, R. Salle, S. Fouere, J.-D. Bouaziz, T.-A. Duong, J.-N. Dauendorffer

引用次数: 0

Dramatic efficacy of omalizumab in a case of severe delayed pressure urticaria in a teenager 奥玛珠单抗治疗青少年严重迟发性压性荨麻疹的显著疗效

IF 2.8 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2025-09-13 DOI: 10.1016/j.annder.2025.103425

N. Kluger , K. Mikola

引用次数: 0

Unilateral localized hyperhidrosis: Eccrine nevus 单侧局部多汗症：汗腺痣

IF 2.8 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2025-09-09 DOI: 10.1016/j.annder.2025.103423

M. Carmi , I. Lafhaj , F. Plantier , E. Carmi

引用次数: 0

Impact of the COVID-19 pandemic on melanoma: A retrospective study from the French clinical database of melanoma patients (RIC-Mel) COVID-19大流行对黑色素瘤的影响：来自法国黑色素瘤患者临床数据库（RIC-Mel）的回顾性研究

IF 2.8 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2025-09-04 DOI: 10.1016/j.annder.2025.103418

F. Skowron , S. Mouret , A. Seigneurin , H. Montaudié , E. Maubec , F. Grange , G. Quereux , P. Célérier , M. Amini-Adle , S. Dalac-Rat , J. De Quatrebarbes , O. Zehou , A. Safia , P. Muller , P. Modiano , L. Misery , N. Litrowski , F. Brunet-Possenti , L. Mortier , G. Bens , M.-T. Leccia

Background

COVID-19 pandemic had a variable impact on the severity of melanomas.

Objective

To assess the role of the COVID-19 pandemic in France on the severity of melanomas at initial diagnosis.

Methods

New melanoma cases recorded in the French RIC-Mel database were included in a retrospective study spanning three timeframes: pre-COVID (01/01/2018 to 03/16/2020), lockdown (03/17/2020 to 10/05/2020), and the COVID pandemic period (hereafter referred to as “COVID”) (11/05/2020 to 30/09/2022). Patient and melanoma characteristics at diagnosis, along with time intervals to lymph node procedures and initiation of systemic treatments, were extracted. Statistical comparisons were conducted between the pre-COVID and COVID periods.

Results

A total of 3650 patients in the pre-COVID period were included: 121 during lockdown, and 2878 during the COVID period. Melanomas diagnosed during the COVID period were thicker (median 1.5 mm; interquartile range [IQR]: 0.7–3.6) compared to those in the pre-COVID period (median 1.2 mm; IQR: 0.5–3.0; p < 0.0001) and more frequently ulcerated (25.4 % vs. 20.6 %; p < 0.0001). The average number of melanomas diagnosed per day decreased from 4.53 (pre-COVID) to 3.30 (COVID), primarily due to reductions in Tis (−32.4 %) and T1 stage diagnoses (−32.5 %).

Adjusted odds ratios (adj OR), accounting for age at diagnosis, sex, personal history of melanoma, and treatment center, indicated increased frequency of advanced tumor stages during the COVID period: T2 (adj OR = 1.23; 95 % confidence interval [CI]: 1.0519–1.459; p = 0.0130), T3 (adj OR = 1.204; 95 % CI: 1.027–1.425; p = 0.0310), and T4 (adj OR = 1.467; 95 % CI: 1.237–1.731; p < 0.001). Stage III cases rose from 6.3 % to 11.9 % (adj OR = 2.05; 95 % CI: 1.67–2.51; p < 0.001). Sentinel lymph node biopsy (SLNB) rates almost doubled (40.3 % vs. 23.4 %; p < 0.001), with a higher positivity rate (adj OR = 1.26; 95 % CI: 1.02–1.56; p = 0.035). Interval times between diagnosis and SLNB, as well as initiation of systemic therapy, remained similar across study periods.

Conclusion

In France, the COVID-19 pandemic was associated with a higher proportion of severe melanoma cases, partially attributed to a reduction in the diagnosis of thin melanomas.

背景：covid -19大流行对黑色素瘤的严重程度有不同的影响。目的探讨法国新冠肺炎疫情对初诊黑色素瘤严重程度的影响。方法将法国RIC-Mel数据库中记录的新黑色素瘤病例纳入回顾性研究，该研究跨越三个时间段：COVID前（2018年1月1日至2020年3月16日）、封锁期（2020年3月17日至2020年10月5日）和COVID大流行期（以下简称“COVID”）（2020年11月5日至2022年9月30日）。患者和黑色素瘤在诊断时的特征，以及淋巴结手术和开始全身治疗的时间间隔，被提取出来。对新冠前和新冠期间进行统计比较。结果共纳入3650例新冠肺炎前患者，其中封锁期121例，新冠肺炎期2878例。与前COVID时期（中位数为1.2 mm; IQR: 0.5-3.0; p <； 0.0001）相比，在COVID期间诊断的黑色素瘤更厚（中位数为1.5 mm；四分位数间距[IQR]: 0.7-3.6），更频繁地溃疡（25.4 %对20.6 %;p <； 0.0001）。平均每天诊断的黑色素瘤数量从4.53例（pre-COVID）下降到3.30例（COVID），主要是由于Tis（- 32.4 %）和T1期诊断（- 32.5 %）的减少。调整后的优势比(adj或),占诊断、年龄性别、个人历史的黑色素瘤,和治疗中心,表示频率增加先进的肿瘤阶段COVID期间:T2 (adj或 = 1.23;95 %可信区间[CI]: 1.0519 - -1.459; p = 0.0130),T3 (adj或 = 1.204;95 % CI: 1.027 - -1.425; p = 0.0310),和T4 (adj或 = 1.467;95 % CI: 1.237 - -1.731; p & lt; 0.001)。III期病例从6.3 %上升到11.9 % （adj OR = 2.05;95 % CI: 1.67-2.51; p <； 0.001）。前哨淋巴结活检(SLNB)率几乎翻了一番(40.3 % 23.4 vs %;p & lt; 0.001),积极性更高速率(adj或 = 1.26;95 % CI: 1.02 - -1.56; p = 0.035)。诊断和SLNB之间的间隔时间，以及开始全身治疗，在研究期间保持相似。在法国，COVID-19大流行与严重黑色素瘤病例比例较高有关，部分原因是薄黑色素瘤的诊断率下降。

{"title":"Impact of the COVID-19 pandemic on melanoma: A retrospective study from the French clinical database of melanoma patients (RIC-Mel)","authors":"F. Skowron , S. Mouret , A. Seigneurin , H. Montaudié , E. Maubec , F. Grange , G. Quereux , P. Célérier , M. Amini-Adle , S. Dalac-Rat , J. De Quatrebarbes , O. Zehou , A. Safia , P. Muller , P. Modiano , L. Misery , N. Litrowski , F. Brunet-Possenti , L. Mortier , G. Bens , M.-T. Leccia","doi":"10.1016/j.annder.2025.103418","DOIUrl":"10.1016/j.annder.2025.103418","url":null,"abstract":"<div><h3>Background</h3><div>COVID-19 pandemic had a variable impact on the severity of melanomas.</div></div><div><h3>Objective</h3><div>To assess the role of the COVID-19 pandemic in France on the severity of melanomas at initial diagnosis.</div></div><div><h3>Methods</h3><div>New melanoma cases recorded in the French RIC-Mel database were included in a retrospective study spanning three timeframes: pre-COVID (01/01/2018 to 03/16/2020), lockdown (03/17/2020 to 10/05/2020), and the COVID pandemic period (hereafter referred to as “COVID”) (11/05/2020 to 30/09/2022). Patient and melanoma characteristics at diagnosis, along with time intervals to lymph node procedures and initiation of systemic treatments, were extracted. Statistical comparisons were conducted between the pre-COVID and COVID periods.</div></div><div><h3>Results</h3><div>A total of 3650 patients in the pre-COVID period were included: 121 during lockdown, and 2878 during the COVID period. Melanomas diagnosed during the COVID period were thicker (median 1.5 mm; interquartile range [IQR]: 0.7–3.6) compared to those in the pre-COVID period (median 1.2 mm; IQR: 0.5–3.0; <em>p</em> < 0.0001) and more frequently ulcerated (25.4 % vs. 20.6 %; <em>p</em> < 0.0001). The average number of melanomas diagnosed per day decreased from 4.53 (pre-COVID) to 3.30 (COVID), primarily due to reductions in Tis (−32.4 %) and T1 stage diagnoses (−32.5 %).</div><div>Adjusted odds ratios (adj OR), accounting for age at diagnosis, sex, personal history of melanoma, and treatment center, indicated increased frequency of advanced tumor stages during the COVID period: T2 (adj OR = 1.23; 95 % confidence interval [CI]: 1.0519–1.459; <em>p</em> = 0.0130), T3 (adj OR = 1.204; 95 % CI: 1.027–1.425; <em>p</em> = 0.0310), and T4 (adj OR = 1.467; 95 % CI: 1.237–1.731; <em>p</em> < 0.001). Stage III cases rose from 6.3 % to 11.9 % (adj OR = 2.05; 95 % CI: 1.67–2.51; <em>p</em> < 0.001). Sentinel lymph node biopsy (SLNB) rates almost doubled (40.3 % vs. 23.4 %; <em>p</em> < 0.001), with a higher positivity rate (adj OR = 1.26; 95 % CI: 1.02–1.56; <em>p</em> = 0.035). Interval times between diagnosis and SLNB, as well as initiation of systemic therapy, remained similar across study periods.</div></div><div><h3>Conclusion</h3><div>In France, the COVID-19 pandemic was associated with a higher proportion of severe melanoma cases, partially attributed to a reduction in the diagnosis of thin melanomas.</div></div>","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"152 4","pages":"Article 103418"},"PeriodicalIF":2.8,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144989214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevalence and characteristics of cold-induced cutaneous and vascular manifestations among runners 跑步者冷致皮肤和血管表现的患病率和特点

IF 2.8 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2025-09-02 DOI: 10.1016/j.annder.2025.103426

N. Kluger , S. Leclerc-Mercier

引用次数: 0

Clinical characteristics, disease burden, and unmet medical needs of generalized pustular psoriasis: Results of the SCRIPTOR study 全身性脓疱性银屑病的临床特征、疾病负担和未满足的医疗需求：SCRIPTOR研究的结果

IF 2.8 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2025-09-02 DOI: 10.1016/j.annder.2025.103427

F. Aubin , E. Wierzbicka-Hainaut , M. Vidal , M. Najean , E. Begon

Background

Generalized pustular psoriasis (GPP) is a rare, severe, chronic neutrophilic skin disease involving the interleukin-36 (IL-36) pathway.

Objective

The main objective of the SCRIPTOR international non-interventional study was to describe sociodemographic and clinical characteristics of GPP. This paper focuses on data collected from participating French centers.

Methods

Patients with a confirmed diagnosis of GPP between 2011 and 2022 were selected by dermatologists from 21 French hospitals. The clinical parameters evaluated included cutaneous and extracutaneous symptoms, and GPP flares in terms of number, duration, and impact. Secondary objectives included the description of treatment patterns.

Results

The analysis included 103 patients. The median age at diagnosis was 59 years. Median follow-up duration was 5 (1 to 11) years. Plaque psoriasis was reported in 48 % of patients. The most frequent comorbidities were hypertension (43 %), diabetes (25 %), dyslipidemia (17 %) and obesity (14 %). Forty-one patients (40 %) experienced flares. The median number of flares per patient was 2 and the median (min–max) duration of episodes was 19 (0–206) days. Treatments mainly included topical steroids and retinoids. Biological therapies were used in less than 10 % of patients at baseline. One death due to septic shock was related to GPP.

Conclusion

This is the largest French chart review study of patients with a confirmed diagnosis of GPP. The nature and prevalence of comorbidities, the length of flare episodes and the number of hospitalizations illustrate the burden of GPP. This study confirms that the impact of GPP should not be underestimated and supports the important need for targeted therapies.

背景：广泛性脓疱性牛皮癣（GPP）是一种罕见的、严重的、慢性中性粒细胞性皮肤病，涉及白细胞介素-36 （IL-36）通路。目的：SCRIPTOR国际非介入研究的主要目的是描述GPP的社会人口学和临床特征。本文着重于从参与的法国中心收集的数据。方法由法国21家医院皮肤科医生选择2011 - 2022年确诊为GPP的患者。评估的临床参数包括皮肤和皮外症状，以及GPP耀斑的数量、持续时间和影响。次要目的包括对治疗模式的描述。结果纳入103例患者。诊断时的中位年龄为59 岁。中位随访时间为5年（1 ~ 11年）。斑块型银屑病在48 %的患者中被报道。最常见的合并症是高血压（43% %）、糖尿病（25% %）、血脂异常（17% %）和肥胖（14% %）。41例患者（40. %）出现耀斑。每位患者的中位数耀斑次数为2次，发作的中位数（最小-最大）持续时间为19（0-206）天。治疗主要包括局部类固醇和类维生素a。在基线时，使用生物疗法的患者不到10% %。1例脓毒性休克死亡与GPP有关。结论：这是法国对确诊为GPP的患者进行的最大的回顾性研究。合并症的性质和流行程度、发作时间和住院次数说明了GPP的负担。这项研究证实，GPP的影响不应被低估，并支持对靶向治疗的重要需求。

{"title":"Clinical characteristics, disease burden, and unmet medical needs of generalized pustular psoriasis: Results of the SCRIPTOR study","authors":"F. Aubin , E. Wierzbicka-Hainaut , M. Vidal , M. Najean , E. Begon","doi":"10.1016/j.annder.2025.103427","DOIUrl":"10.1016/j.annder.2025.103427","url":null,"abstract":"<div><h3>Background</h3><div>Generalized pustular psoriasis (GPP) is a rare, severe, chronic neutrophilic skin disease involving the interleukin-36 (IL-36) pathway.</div></div><div><h3>Objective</h3><div>The main objective of the SCRIPTOR international non-interventional study was to describe sociodemographic and clinical characteristics of GPP. This paper focuses on data collected from participating French centers.</div></div><div><h3>Methods</h3><div>Patients with a confirmed diagnosis of GPP between 2011 and 2022 were selected by dermatologists from 21 French hospitals. The clinical parameters evaluated included cutaneous and extracutaneous symptoms, and GPP flares in terms of number, duration, and impact. Secondary objectives included the description of treatment patterns.</div></div><div><h3>Results</h3><div>The analysis included 103 patients. The median age at diagnosis was 59 years. Median follow-up duration was 5 (1 to 11) years<em>.</em> Plaque psoriasis was reported in 48 % of patients. The most frequent comorbidities were hypertension (43 %), diabetes (25 %), dyslipidemia (17 %) and obesity (14 %). Forty-one patients (40 %) experienced flares. The median number of flares per patient was 2 and the median (min–max) duration of episodes was 19 (0–206) days. Treatments mainly included topical steroids and retinoids. Biological therapies were used in less than 10 % of patients at baseline. One death due to septic shock was related to GPP.</div></div><div><h3>Conclusion</h3><div>This is the largest French chart review study of patients with a confirmed diagnosis of GPP. The nature and prevalence of comorbidities, the length of flare episodes and the number of hospitalizations illustrate the burden of GPP. This study confirms that the impact of GPP should not be underestimated and supports the important need for targeted therapies.</div></div>","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"152 4","pages":"Article 103427"},"PeriodicalIF":2.8,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144932574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Atypical dermatomycosis caused by Alternaria infectoria. 由交替菌感染引起的非典型皮肤真菌病。

IF 2.8 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2025-09-01 Epub Date: 2025-08-07 DOI: 10.1016/j.annder.2025.103401

F Le Lay, J-M L'Orphelin, M Mouthon, P Lecanu

引用次数: 0

Lupus vulgaris in a teenager. 青少年的寻常性狼疮。

IF 2.8 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2025-09-01 Epub Date: 2025-08-07 DOI: 10.1016/j.annder.2025.103399

S Dalla Vecchia, A C Pisani Pulita, L N Takeda, A E Kiszewski

引用次数: 0

Mammary and extramammary diffuse dermal angiomatosis: a case series and review of the literature. 乳腺及乳腺外弥漫性真皮血管瘤病：病例系列及文献回顾。

IF 2.8 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2025-09-01 Epub Date: 2025-08-07 DOI: 10.1016/j.annder.2025.103397

C Decaestecker, E Diaz, E Crickx, J-D Bouaziz, C Vanhaecke, M-A Viguier, E Brenaut, D Kottler, P Courville, C Tamarit, M Battistella, C Bocciarelli, G Leflahec, C Emonet, P Carvalho, B Tedbirt

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Annales De Dermatologie Et De Venereologie

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀